Les cancers en France -Edition 2013 -Publications -Institut National Du Cancer. at <http://www.e-cancer.fr/publications/69-epidemiologie/758-les-cancers-en-france-edition-2013> 2. Bigot, F. et al. Évolution épidémiologique du cancer broncho-pulmonaire en France et en, Europe. Rev. Mal. Respir. Actual, vol.5, pp.321-324, 2013. ,
The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends, Journal of Thoracic Oncology, vol.3, issue.8, pp.819-831, 2008. ,
DOI : 10.1097/JTO.0b013e31818020eb
Fact Sheets by Population. at <http://globocan.iarc.fr/Pages//fact_sheets_ population.aspx> 5. INCa. Aspects économiques des coûts du cancer en France, pp.1286-4265, 2007. ,
European cancer mortality predictions for the year 2014, Annals of Oncology, vol.25, issue.8, pp.1650-1656, 2014. ,
DOI : 10.1093/annonc/mdu138
Cancer incidence and mortality in France over the 1980?2012 period: Solid tumors. Rev. D'Épidémiologie Santé Publique 62, pp.95-108, 2014. ,
Lung Cancer Fact Sheet American Lung Association (2014) at <http://www.lung.org/lung-disease/lung-cancer/resources/facts-figures/lung-cancer-factsheet .html> 9. Horner, J. W. SEER Cancer Statistics Review 1975-2006 -Previous Version -SEER Cancer Statistics, 2006. ,
Tendances 76 -Les niveaux d'usage des drogues en France en 2010, 2011. ,
Tobacco epidemiology, Rev. Prat, vol.62, issue.325, pp.327-329, 2012. ,
Smoking and Tobacco Use; 50th Anniversary Surgeon General's Report. Smoking and Tobacco Use, 2012. ,
Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries, The Lancet, vol.377, issue.9760, pp.139-146, 2011. ,
DOI : 10.1016/S0140-6736(10)61388-8
Genomic impact of cigarette smoke, with application to three smoking-related diseases, Critical Reviews in Toxicology, vol.107, issue.10, pp.877-889, 2012. ,
DOI : 10.1165/rcmb.2007-0379OC
Mutagenicity of 11 cigarette smoke condensates in two versions of the mouse lymphoma assay, Mutagenesis, vol.26, issue.2, pp.273-281, 2011. ,
DOI : 10.1093/mutage/geq083
Relationship between TP53 tumour suppressor gene mutations and smoking-related bulky DNA adducts in a lung cancer study population from Hungary, Mutagenesis, vol.24, issue.6, pp.475-480, 2009. ,
DOI : 10.1093/mutage/gep031
Mortality in relation to smoking: 50 years' observations on male British doctors, BMJ, vol.328, issue.7455, pp.1519-1519, 2004. ,
DOI : 10.1136/bmj.38142.554479.AE
Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis, BMJ, vol.340, issue.jan21 1, pp.5569-5569, 2010. ,
DOI : 10.1136/bmj.b5569
Cannabis use and risk of lung cancer: a case-control study, European Respiratory Journal, vol.31, issue.2, pp.280-286, 2008. ,
DOI : 10.1183/09031936.00065707
Marijuana and lung diseases, Current Opinion in Pulmonary Medicine, vol.20, issue.2, pp.173-179, 2014. ,
DOI : 10.1097/MCP.0000000000000026
Cancer broncho-pulmonaire, nouvelle approche ??pid??miologique, Revue des Maladies Respiratoires Actualit??s, vol.5, issue.5, pp.581-590, 2013. ,
DOI : 10.1016/S1877-1203(13)70456-7
Lung Cancer in Radon-Exposed Miners and Estimation of Risk From Indoor Exposure, JNCI Journal of the National Cancer Institute, vol.87, issue.11, pp.817-827, 1995. ,
DOI : 10.1093/jnci/87.11.817
Lung Cancer Attributable to Indoor Radon Exposure in France: Impact of the Risk Models and Uncertainty Analysis, Environmental Health Perspectives, vol.114, issue.9, pp.1361-1366, 2006. ,
DOI : 10.1289/ehp.9070
URL : https://hal.archives-ouvertes.fr/inserm-00138827
Additive Synergism between Asbestos and Smoking in Lung Cancer Risk: A Systematic Review and Meta-Analysis, PLOS ONE, vol.153, issue.8, 2015. ,
DOI : 10.1371/journal.pone.0135798.s003
Cancer bronchique de la femme et de la femme enceinte : vers une origine hormonale ?, Revue des Maladies Respiratoires, vol.24, issue.8, pp.983-997, 2007. ,
DOI : 10.1016/S0761-8425(07)92763-1
The 2015 World Health Organization Classification of Lung Tumors, Journal of Thoracic Oncology, vol.10, issue.9, pp.10-10970000000000000630, 2015. ,
DOI : 10.1097/JTO.0000000000000630
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma, Journal of Thoracic Oncology, vol.6, issue.2, pp.244-285, 2011. ,
DOI : 10.1097/JTO.0b013e318206a221
URL : https://hal.archives-ouvertes.fr/inserm-00561753
Histologic features are important prognostic indicators in early stages lung adenocarcinomas, Modern Pathology, vol.67, issue.2, pp.233-241, 2006. ,
DOI : 10.1038/modpathol.3800734
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours, Journal of Thoracic Oncology, vol.2, issue.8, pp.706-714, 2007. ,
DOI : 10.1097/JTO.0b013e31812f3c1a
The ErbB receptors and their role in cancer progression, Experimental Cell Research, vol.284, issue.1, pp.99-110, 2003. ,
DOI : 10.1016/S0014-4827(02)00099-X
Epidermal growth factor receptor: mechanisms of activation and signalling, Experimental Cell Research, vol.284, issue.1, pp.31-53, 2003. ,
DOI : 10.1016/S0014-4827(02)00098-8
Comparing antibody and small-molecule therapies for cancer, Nature Reviews Cancer, vol.23, issue.9, pp.714-727, 2006. ,
DOI : 10.1038/nrc1913
Un regard simple sur la biologie du cancer bronchique??: EGFR, Revue des Maladies Respiratoires, vol.28, issue.4, pp.565-577, 2011. ,
DOI : 10.1016/j.rmr.2011.03.005
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy, Clinical Cancer Research, vol.12, issue.18, pp.5268-5272, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-1554
Frequent Expression of a Mutant Epidermal Growth Factor Receptor in Multiple Human Tumors, Cancer Res, vol.55, pp.5536-5539, 1995. ,
The EGF receptor family as targets for cancer therapy. Publ. Online 08 Febr, 2001. ,
Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL, Cell, vol.87, issue.4, pp.619-628, 1996. ,
DOI : 10.1016/S0092-8674(00)81382-3
Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology., Molecular Biology of the Cell, vol.4, issue.1, pp.121-133, 1993. ,
DOI : 10.1091/mbc.4.1.121
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity., Proc. Natl. Acad. Sci. 91, pp.7727-7731, 1994. ,
DOI : 10.1073/pnas.91.16.7727
Epidermal growth factor receptor mutations in lung cancer, Nature Reviews Cancer, vol.64, issue.3, pp.169-181, 2007. ,
DOI : 10.1038/nrc2088
Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma, Critical Reviews in Oncology/Hematology, vol.88, issue.3, pp.477-493, 2013. ,
DOI : 10.1016/j.critrevonc.2013.06.009
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.21, issue.12, pp.2237-2246, 2003. ,
DOI : 10.1200/JCO.2003.10.038
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non???Small Cell Lung Cancer, JAMA, vol.290, issue.16, pp.2149-2158, 2003. ,
DOI : 10.1001/jama.290.16.2149
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non???Small-Cell Lung Cancer to Gefitinib, New England Journal of Medicine, vol.350, issue.21, pp.2129-2139, 2004. ,
DOI : 10.1056/NEJMoa040938
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy, Science, vol.304, issue.5676, pp.1497-1500, 2004. ,
DOI : 10.1126/science.1099314
Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline, Clinical Therapeutics, vol.35, issue.9, pp.1282-1303, 2013. ,
DOI : 10.1016/j.clinthera.2013.08.007
COSMIC 2005, British Journal of Cancer, vol.57, issue.2, pp.318-322, 2005. ,
DOI : 10.1126/science.1096096
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors, Oncogene, vol.19, pp.24-31, 2009. ,
DOI : 10.1016/j.cell.2006.05.013
EGFR Mutations in Lung Adenocarcinomas, The Journal of Molecular Diagnostics, vol.10, issue.3, pp.242-248, 2008. ,
DOI : 10.2353/jmoldx.2008.070178
Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity, Cancer Cell, vol.11, issue.3, pp.217-227, 2007. ,
DOI : 10.1016/j.ccr.2006.12.017
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers, JNCI Journal of the National Cancer Institute, vol.97, issue.5, pp.339-346, 2005. ,
DOI : 10.1093/jnci/dji055
Gefitinib or Carboplatin???Paclitaxel in Pulmonary Adenocarcinoma, New England Journal of Medicine, vol.361, issue.10, pp.947-957, 2009. ,
DOI : 10.1056/NEJMoa0810699
Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas, Journal of Clinical Oncology, vol.24, issue.11, pp.1700-1704, 2006. ,
DOI : 10.1200/JCO.2005.04.3224
Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non???Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials, Journal of Clinical Oncology, vol.23, issue.31, pp.8081-8092, 2005. ,
DOI : 10.1200/JCO.2005.02.7078
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study, The Lancet Oncology, vol.11, issue.6, pp.521-529, 2010. ,
DOI : 10.1016/S1470-2045(10)70112-1
Erlotinib in Previously Treated Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.353, issue.2, pp.123-132, 2005. ,
DOI : 10.1056/NEJMoa050753
Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer, Journal of Clinical Oncology, vol.26, issue.10, pp.1742-1751, 2008. ,
DOI : 10.1200/JCO.2007.12.1178
Complex Mutations in the Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer, Journal of Thoracic Oncology, vol.5, issue.10, pp.1524-1528, 2010. ,
DOI : 10.1097/JTO.0b013e3181e8b3c5
V843I Germ-Line Mutation, Journal of Clinical Oncology, vol.29, issue.8, pp.191-192, 2011. ,
DOI : 10.1200/JCO.2010.31.4492
Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions, Journal of Thoracic Oncology, vol.8, issue.2, pp.179-184, 2013. ,
DOI : 10.1097/JTO.0b013e3182779d18
Epidermal growth factor-related peptides and their receptors in human malignancies, Critical Reviews in Oncology/Hematology, vol.19, issue.3, pp.183-232, 1995. ,
DOI : 10.1016/1040-8428(94)00144-I
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology, Archives of Pathology & Laboratory Medicine, vol.137, issue.6, pp.828-860, 2013. ,
DOI : 10.5858/arpa.2012-0720-OA.s1
A view on EGFR-targeted therapies from the oncogene-addiction perspective, Frontiers in Pharmacology, vol.4, 2013. ,
DOI : 10.3389/fphar.2013.00053
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594, Cancer, vol.11, issue.10, pp.2639-2647, 2001. ,
DOI : 10.1002/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, The Lancet Oncology, vol.13, issue.3, pp.239-246, 2012. ,
DOI : 10.1016/S1470-2045(11)70393-X
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, openlabel , ENSURE study, Ann. Oncol, vol.270, 2015. ,
Clinical Course of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib, Clinical Cancer Research, vol.12, issue.3, pp.839-844, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-1846
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, The Lancet Oncology, vol.11, issue.2, pp.121-128, 2010. ,
DOI : 10.1016/S1470-2045(09)70364-X
Gefitinib or Chemotherapy for Non???Small-Cell Lung Cancer with Mutated EGFR, New England Journal of Medicine, vol.362, issue.25, pp.2380-2388, 2010. ,
DOI : 10.1056/NEJMoa0909530
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung, Journal of Clinical Oncology, vol.30, issue.10, pp.1122-1128, 2012. ,
DOI : 10.1200/JCO.2011.36.8456
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models, Oncogene, vol.6, issue.34, pp.4702-4711, 2008. ,
DOI : 10.1016/j.ccr.2006.05.023
Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review, Onkologie, vol.36, issue.9, pp.5-5, 2013. ,
DOI : 10.1159/000354627
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial, The Lancet Oncology, vol.15, issue.2, pp.213-222, 2014. ,
DOI : 10.1016/S1470-2045(13)70604-1
Mutations, Journal of Clinical Oncology, vol.31, issue.27, pp.3327-3334, 2013. ,
DOI : 10.1200/JCO.2012.44.2806
Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) ASCO Meet, Abstr, vol.32, p.8004, 2014. ,
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, The Lancet Oncology, vol.12, issue.8, pp.735-742, 2011. ,
DOI : 10.1016/S1470-2045(11)70184-X
First-Line Gefitinib for Patients With Advanced Non???Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy, Journal of Clinical Oncology, vol.27, issue.9, pp.1394-1400, 2009. ,
DOI : 10.1200/JCO.2008.18.7658
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer, New England Journal of Medicine, vol.361, issue.10, pp.958-967, 2009. ,
DOI : 10.1056/NEJMoa0904554
Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non???Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials, Clinical Lung Cancer, vol.13, issue.2, pp.107-114, 2012. ,
DOI : 10.1016/j.cllc.2011.08.005
Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis, JNCI Journal of the National Cancer Institute, vol.105, issue.9, pp.595-605, 2013. ,
DOI : 10.1093/jnci/djt072
Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial, Journal of Clinical Oncology, vol.30, issue.17, pp.2063-2069, 2012. ,
DOI : 10.1200/JCO.2011.40.1315
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study, The Lancet Oncology, vol.15, issue.11, pp.1236-1244, 2014. ,
DOI : 10.1016/S1470-2045(14)70381-X
Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different? [Review]. Anti-Cancer Drugs Novemb, pp.856-866, 2009. ,
Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes, Clinical Cancer Research, vol.13, issue.12, pp.3731-3737, 2007. ,
DOI : 10.1158/1078-0432.CCR-07-0088
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study, The Lancet, vol.374, issue.9699, pp.1432-1440, 2009. ,
DOI : 10.1016/S0140-6736(09)61497-5
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non???Small-Cell Lung Cancer Previously Treated With Chemotherapy, Journal of Clinical Oncology, vol.22, issue.9, pp.1589-1597, 2004. ,
DOI : 10.1200/JCO.2004.08.163
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer), The Lancet, vol.366, issue.9496, pp.1527-1537, 2005. ,
DOI : 10.1016/S0140-6736(05)67625-8
Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.27, issue.11, pp.1836-1843, 2009. ,
DOI : 10.1200/JCO.2008.17.5844
Prise en charge thérapeutique du cancer du poumon non à petites cellules : synthèse des recommandations at <http://www.e-cancer.fr/component/docman/doc_download/9609- prise-en-charge-therapeutique-du-cancer-du-poumon-non-a-petites-cellules-synthese-des- recommandations>, 2010. ,
Tumor Immunotherapy Directed at PD-1, New England Journal of Medicine, vol.366, issue.26, pp.2517-2519, 2012. ,
DOI : 10.1056/NEJMe1205943
Immune Checkpoint Modulation for Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.21, issue.10, pp.2256-2262, 2015. ,
DOI : 10.1158/1078-0432.CCR-14-2959
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation, Journal of Thoracic Oncology, vol.10, issue.6, pp.910-923, 2015. ,
DOI : 10.1097/JTO.0000000000000500
Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology, Annals of Oncology, vol.25, issue.7, pp.1270-1283, 2014. ,
DOI : 10.1093/annonc/mdu022
Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy, Lung Cancer, vol.79, issue.2, pp.167-172, 2013. ,
DOI : 10.1016/j.lungcan.2012.10.010
Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer, J. Natl. Cancer Inst, vol.91, pp.66-72, 1999. ,
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial, The Lancet, vol.378, issue.9796, pp.1079-1088, 2011. ,
DOI : 10.1016/S0140-6736(11)60780-0
URL : https://hal.archives-ouvertes.fr/hal-00718837
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials, Clinical Cancer Research, vol.15, issue.16, pp.5267-5273, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-0888
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.28, issue.2, pp.357-360, 2010. ,
DOI : 10.1200/JCO.2009.24.7049
Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation???diversity, ductility, and destiny, Cancer and Metastasis Reviews, vol.4, issue.5, pp.807-814, 2012. ,
DOI : 10.1007/s10555-012-9391-7
EGFR-T790M Is a Rare Lung Cancer Susceptibility Allele with Enhanced Kinase Activity, Cancer Research, vol.67, issue.10, pp.4665-4670, 2007. ,
DOI : 10.1158/0008-5472.CAN-07-0217
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins, Cancer Treatment Reviews, vol.40, issue.1, pp.93-101, 2014. ,
DOI : 10.1016/j.ctrv.2013.06.002
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP, Proc. Natl. Acad. Sci. 105, pp.2070-2075, 2008. ,
DOI : 10.1073/pnas.0709662105
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation, Clinical Cancer Research, vol.17, issue.6, pp.1616-1622, 2011. ,
DOI : 10.1158/1078-0432.CCR-10-2692
Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma, Clinical Cancer Research, vol.14, issue.18, pp.5731-5734, 2008. ,
DOI : 10.1158/1078-0432.CCR-08-0646
The ras gene family and human carcinogenesis, Mutation Research/Reviews in Genetic Toxicology, vol.195, issue.3, pp.255-271, 1988. ,
DOI : 10.1016/0165-1110(88)90004-8
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study, The Lancet Oncology, vol.14, issue.1, pp.38-47, 2013. ,
DOI : 10.1016/S1470-2045(12)70489-8
The deaf and the dumb: the biology of ErbB-2 and ErbB-3, Experimental Cell Research, vol.284, issue.1, pp.54-65, 2003. ,
DOI : 10.1016/S0014-4827(02)00101-5
Mutation, Cancer Discovery, vol.2, issue.10, pp.922-933, 2012. ,
DOI : 10.1158/2159-8290.CD-12-0108
Mutation: Epidemiologic Characteristics and Therapeutic Perspectives, Journal of Clinical Oncology, vol.31, issue.16, p.6095, 2012. ,
DOI : 10.1200/JCO.2012.45.6095
Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas, Clinical Cancer Research, vol.18, issue.18, pp.4910-4918, 2012. ,
DOI : 10.1158/1078-0432.CCR-12-0912
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer, FEBS Journal, vol.22, issue.2, pp.301-308, 2010. ,
DOI : 10.1111/j.1742-4658.2009.07448.x
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors, Cancer Cell, vol.10, issue.1, pp.25-38, 2006. ,
DOI : 10.1016/j.ccr.2006.05.023
Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.19, issue.16, pp.4532-4540, 2013. ,
DOI : 10.1158/1078-0432.CCR-13-0657
Mutations, Journal of Clinical Oncology, vol.29, issue.15, pp.2046-2051, 2011. ,
DOI : 10.1200/JCO.2010.33.1280
Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer, Cancer Research, vol.68, issue.22, pp.9375-9383, 2008. ,
DOI : 10.1158/0008-5472.CAN-08-2223
Met, metastasis, motility and more, Nature Reviews Molecular Cell Biology, vol.4, issue.12, pp.915-925, 2003. ,
DOI : 10.1038/nrm1261
Invasive growth: a MET-driven genetic programme for cancer and stem cells, Nature Reviews Cancer, vol.16, issue.8, pp.637-645, 2006. ,
DOI : 10.1038/nrc1912
Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Publ. Online 20 Novemb, 2000. ,
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling, Science, vol.316, issue.5827, pp.1039-1043, 2007. ,
DOI : 10.1126/science.1141478
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib, Proc. Natl. Acad. Sci, pp.20932-20937, 2007. ,
DOI : 10.1073/pnas.0710370104
Efficacy and safety of crizotinib in patients with advanced c-METamplified non-small cell lung cancer (NSCLC) ASCO Meet, Abstr, vol.32, p.8001, 2014. ,
The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit, Oncogene, vol.10, pp.739-749, 1995. ,
Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort, J. Thorac. Oncol, 2011. ,
Activation of the PD-1 pathway contributes to immune escape in EGFRdriven lung tumors, Cancer Discov, vol.3, 2013. ,
Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? Clin. Cancer Res, pp.64-76, 2012. ,
Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer, Lung Cancer, vol.76, issue.1, pp.26-31, 2012. ,
DOI : 10.1016/j.lungcan.2011.09.011
Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC), ASCO Meet. Abstr, vol.30, p.7543, 2012. ,
-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, Journal of Clinical Oncology, vol.33, issue.15, pp.1666-1673, 2015. ,
DOI : 10.1200/JCO.2014.59.7328
URL : https://hal.archives-ouvertes.fr/jpa-00210025
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors, Science Translational Medicine, vol.3, issue.75, pp.75-101, 2011. ,
DOI : 10.1126/scitranslmed.3002003
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer, Nature Genetics, vol.88, issue.8, pp.852-860, 2012. ,
DOI : 10.2353/jmoldx.2010.090140
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin, The Lancet Oncology, vol.16, issue.4, pp.165-172, 2015. ,
DOI : 10.1016/S1470-2045(14)71180-5
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-247, 2009. ,
DOI : 10.1016/j.ejca.2008.10.026
Les tests de génétique moléculaire pour l'accès aux thérapies ciblées en 2012 -Ref : BILTESTGEN12 | Institut National Du Cancer at <http://www.e-cancer.fr/Expertises-et- publications/Catalogue-des-publications/Les-tests-de-genetique-moleculaire-pour-l-acces-aux- therapies-ciblees-en-2012>, 2012. ,
Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib, Clinical Cancer Research, vol.12, issue.13, pp.3908-3914, 2006. ,
DOI : 10.1158/1078-0432.CCR-06-0462
Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation???Positive Non???Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib, Journal of Thoracic Oncology, vol.9, issue.2, pp.200-204, 2014. ,
DOI : 10.1097/JTO.0000000000000053
Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?, Journal of Translational Medicine, vol.12, issue.1, p.131, 2014. ,
DOI : 10.1016/S1525-1578(10)60006-2
URL : https://hal.archives-ouvertes.fr/inserm-00998916
Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC, Targeted Oncology, vol.359, issue.4, pp.247-253, 2014. ,
DOI : 10.1007/s11523-014-0332-y
Repeat Biopsy for Mutational Analysis of Non???Small Cell Lung Cancers Resistant to Previous Chemotherapy: Adequacy and Complications, Radiology, vol.265, issue.3, pp.939-948, 2012. ,
DOI : 10.1148/radiol.12112613
Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer, International Journal of Cancer, vol.23, issue.1, pp.247-255, 2010. ,
DOI : 10.1002/ijc.24657
Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, The Oncologist, vol.18, issue.11, pp.1214-1220, 2013. ,
DOI : 10.1634/theoncologist.2013-0168
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Metastatic to the Brain, Clinical Cancer Research, vol.18, issue.4, pp.938-944, 2012. ,
DOI : 10.1158/1078-0432.CCR-11-2529
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer, Neuro-Oncology, vol.13, issue.12, pp.1364-1369, 2011. ,
DOI : 10.1093/neuonc/nor121
Response and Resistance in a Non???Small-Cell Lung Cancer Patient With an Epidermal Growth Factor Receptor Mutation and Leptomeningeal Metastases Treated With High-Dose Gefitinib, Journal of Clinical Oncology, vol.24, issue.27, pp.4517-4520, 2006. ,
DOI : 10.1200/JCO.2006.06.6126
Randomized Phase II Study of Pulse Erlotinib Before or After Carboplatin and Paclitaxel in Current or Former Smokers With Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.27, issue.2, pp.264-270, 2009. ,
DOI : 10.1200/JCO.2008.17.4656
Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, Journal of Thoracic Oncology, vol.8, issue.3, pp.346-351, 2013. ,
DOI : 10.1097/JTO.0b013e31827e1f83
Whole brain radiotherapy for brain metastasis, Surg. Neurol. Int, vol.4, pp.236-244, 2013. ,
Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.31, issue.7, pp.895-902, 2013. ,
DOI : 10.1200/JCO.2011.40.1174
Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer, ASCO Meet. Abstr, vol.30, p.7547, 2012. ,
Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?, Clinical and Translational Oncology, vol.92, issue.3, pp.959-964, 2013. ,
DOI : 10.1007/s12094-013-1035-z
Mutation and Resistance of Non???Small-Cell Lung Cancer to Gefitinib, New England Journal of Medicine, vol.352, issue.8, pp.786-792, 2005. ,
DOI : 10.1056/NEJMoa044238
Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design, Clinical Cancer Research, vol.17, issue.19, pp.6298-6303, 2011. ,
DOI : 10.1158/1078-0432.CCR-11-1468
Disease flare after gefitinib discontinuation, Respiratory Investigation, vol.53, issue.2, pp.68-72, 2015. ,
DOI : 10.1016/j.resinv.2014.10.005
1223OASPIRATION: FIRST-LINE ERLOTINIB (E) UNTIL AND BEYOND RECIST PROGRESSION (PD) IN ASIAN PATIENTS (PTS) WITH EGFR MUTATION-POSITIVE (MUT+) NSCLC, Annals of Oncology, vol.25, issue.suppl_4, pp.426-470, 2014. ,
DOI : 10.1093/annonc/mdu349.2
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer, Lung Cancer, vol.79, issue.1, pp.33-39, 2013. ,
DOI : 10.1016/j.lungcan.2012.09.016
A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment, Lung Cancer, vol.82, issue.2, pp.299-304, 2013. ,
DOI : 10.1016/j.lungcan.2013.08.009
Subsequent Treatment Choices for Patients with Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer: Restore after a Drug Holiday or Switch to another EGFR-TKI?, Asian Pacific Journal of Cancer Prevention, vol.15, issue.1, pp.205-213, 2014. ,
DOI : 10.7314/APJCP.2014.15.1.205
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib, Clinical Cancer Research, vol.14, issue.21, pp.7060-7067, 2008. ,
DOI : 10.1158/1078-0432.CCR-08-1455
Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling, Science Translational Medicine, vol.3, issue.90, pp.90-59, 2011. ,
DOI : 10.1126/scitranslmed.3002356
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial, The Lancet Oncology, vol.16, issue.8, pp.990-998, 2015. ,
DOI : 10.1016/S1470-2045(15)00121-7
AZD9291 in EGFR Inhibitor???Resistant Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.372, issue.18, pp.1689-1699, 2015. ,
DOI : 10.1056/NEJMoa1411817
-Mutated Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.372, issue.18, pp.1700-1709, 2015. ,
DOI : 10.1056/NEJMoa1413654
Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002, Clinical Cancer Research, vol.20, issue.17, pp.4613-4624, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-3063
Circulating Deoxyribonucleic Acid As Prognostic Marker in Non???Small-Cell Lung Cancer Patients Undergoing Chemotherapy, Journal of Clinical Oncology, vol.22, issue.20, pp.4157-4164, 2004. ,
DOI : 10.1200/JCO.2004.11.123
Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis, Scientific Reports, vol.23, 2014. ,
DOI : 10.1038/srep06269